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In order to combat chronic immune disorders (CIDs), it is an absolute necessity to 
understand the bigger picture, one that goes beyond insights at a one-disease, molec-
ular, cellular, and static level. To unravel this bigger picture we advocate an integral, 
 cross-disciplinary approach capable of embracing the complexity of the field. This paper 
discusses the current knowledge on common pathways in CIDs including general psycho-
social and lifestyle factors associated with immune functioning. We demonstrate the lack 
of more in-depth psychosocial and lifestyle factors in current research cohorts and most 
importantly the need for an all-encompassing analysis of these factors. The second part 
of the paper discusses the challenges of understanding immune system dynamics and 
effectively integrating all key perspectives on immune functioning, including the patient’s 
perspective itself. This paper suggests the use of techniques from complex systems 
science in describing and simulating healthy or deviating behavior of the immune system 
in its biopsychosocial surroundings. The patient’s perspective data are suggested to be 
generated by using specific narrative techniques. We conclude that to gain more insight 
into the behavior of the whole system and to acquire new ways of combatting CIDs, we 
need to construct and apply new techniques in the field of computational and complexity 
science, to an even wider variety of dynamic data than used in today’s systems medicine.
Keywords: chronic immune disorders, common pathways, data integration, life style, psychosocial factors
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iNtrODUctiON
Chronic immune disorders (CIDs), comprising chronic immune-
mediated inflammatory conditions, such as autoimmune 
diseases, allergies, immune deficiencies, and some psychiatric 
disorders (such as depression) are a large and growing health 
problem. Approximately 1 in 10 individuals living in Europe and 
North America are affected, and consequently, CIDs represent 
a significant cause of chronic morbidity and disability (1, 2), 
strongly impacting the quality of life.
This translates into a substantial (socio)economic challenge to 
rapidly improve prediction, prevention, diagnosis, and treatment 
of these diseases in order to significantly reduce health-care costs1 
(3–5).
More than 50 years of immunological research has brought us 
detailed insights into immune pathways at both a molecular and 
cellular level but still leaves fundamental questions unanswered: 
which (common) factors contribute to the onset of CIDs and 
which mechanisms keep the immune system in homeostasis or 
can drive the system into disease states?
In order to combat CIDs, we need to understand the bigger 
picture that goes beyond insights at a one-disease, molecular, 
cellular, and static level. To unravel this bigger picture we should 
use an integral, cross-disciplinary approach (6, 7). Although the 
idea of such an approach is not entirely new, most challenges to 
transform it into truly integral scientific pan-disease projects are 
still to be met. It is crucial to embrace the complexity of the CID 
field and boldly start applying new techniques from the field of 
complex systems science to effectively combine different scientific 
perspectives, including the human (patient) perspective.
tHe BiGGer PictUre
In order to gain more insight into the driving mechanisms 
underlying CIDs we need to broaden our current reductionistic 
focus on molecular, cellular, and organ level of a single CID to a 
holistic strategy that considers multiple CIDs and incorporates 
the microbiome, psychological, social, and lifestyle determinants. 
Although several projects and consortia exist worldwide that 
incorporate some of the aforementioned immune parameters 
and general psychosocial aspects, a number of key factors are 
lacking. An all-encompassing analysis is needed. Here, we will 
provide a more detailed insight into factors that in our opinion 
could contribute to this bigger picture (Figure 1A).
cOMMON PAtHWAYs iN ciDs
The existence of common pathogenic pathways in different types 
of CIDs indicates that in addition to focusing on single CID 
research we should make an effort to understand the common-
alities of CIDs. In recent years, a large number of genome-wide 
association studies (GWAS) for CIDs have been performed to 
identify single nucleotide polymorphisms (SNPs) associated with 
disease phenotypes. Several hundreds of disease-associated SNPs 
1 http://www.who.int/ncds/introduction/en/.
have been identified including a large number of variants that are 
shared between CIDs (8–10). For the interpretation of the GWAS 
findings, the first steps are taken to understand the function of 
individual genes, their interactions, and to get insights into how 
these genetic variants are associated with the underlying immune 
disease (11–16). Follow-up studies should also incorporate epi-
genetics, transcriptomics, proteomics, and genome engineering 
to understand the functional relevance of SNPs (17, 18). Patient 
stratification based on cell-specific transcriptomic data was 
recently reported (19, 20). In addition, comorbidity of immune 
disorders, for example, in patients with inflammatory bowel dis-
eases, psoriasis, or rheumatoid arthritis (21, 22) demonstrates that 
common mechanisms probably underlie immune disorders (23). 
Recent work in the field of systems medicine (24, 25) shows com-
monalities at the molecular and cellular level between subgroups 
of patients diagnosed with different CIDs. Also, indications that 
most of the CIDs share the same effector mechanisms and path-
ways of inflammation can be exemplified by the observation that 
specific therapeutic approaches in one specific CID can often be 
used in another CID as well. Examples are the use of anti-TNFα 
treatment in rheumatoid arthritis, psoriasis, and IBD (26–28) and 
targeting the IL-12/IL-23 pathway in various other CIDs (29). We 
can conclude that, despite the presentation of different clinical 
symptoms and involvement of different organs, distinct CIDs 
share common immune mechanisms.
General Psychosocial and Lifestyle 
Factors Associated with immune 
Functioning
Next to genetic or physiological processes related to immune 
functioning, other general factors might impact immune func-
tioning in both healthy individuals and patients with CIDs. It is 
important to look into the evidence regarding the role of psy-
chosocial and lifestyle factors on different elements of immune 
system functioning, as an insight into these factors may provide 
leads to improved immune functioning in immunocompromised 
populations by means of non-invasive, non-medical strategies.
Psychosocial Factors
There is convincing evidence supporting a role of psychosocial 
factors in influencing immune processes and inflammatory 
function in both healthy and immunocompromised conditions. 
For example, since the seminal paper by Cohen and colleagues 
(30), consistent evidence has been reported for the link between 
both acute and chronic psychological stress and the suppres-
sion of immune system functioning (e.g., percentage of T sup-
pressor/cytotoxic cells, levels of pro-inflammatory cytokines, 
and antibody response to immunization) (31–33). Next to the 
role of stress exposure, cognitive behavioral ways of dealing 
with stress, such as more passive-avoidant coping, and social 
resources, for instance, lack of social support, influence longer-
term immune-related outcomes, such as disease progression, as 
shown for example in natural course studies of acute infections 
or patients with chronic inflammatory diseases (31). Although 
more research is needed into the mechanisms that underlie the 
association between psychological factors and immune system 
FiGUre 1 | immune functioning: embracing complexity. (A) A wide variety of determinants influencing immune function. (B) Process overview of the immune 
system behavior. (c) Qualitative criteria for the behavior of the immune system. At step 2 “recognize and localize” the system must be able to discriminate between 
true threats and harmless organisms or cells. The discriminating capacity of the system might be low in disorders like allergies, some autoimmune diseases, and 
immunodeficiencies. Between steps 3 and 5, the swiftness or speed of alarming, mobilizing, and destroying is key for the immune system’s effectiveness in 
combatting pathogens before they start growing or mutating. The same applies to the thoroughness of destroying and cleaning up pathogens in steps 5 and 6 so 
that no or very little strain on the body remains after the infection. The capacity to restore any damage after the infection at step 7 and the speed at which the 
system returns to an attemptive calmness is an often forgotten aspect of the immune system’s capabilities. In autoimmune diseases, this might be disrupted. In 
conclusion, the whole duration of the immune reaction to a certain pathogen can also be an indicator for (un)healthy behavior. Icons in panels (B,c) made by 
Katarina Stefanikova (lightning cloud) and Freepik (other icons) are from www.flaticon.com.
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functioning, the available evidence suggests that corresponding 
psychosocial factors impact generic inflammatory parameters of 
immune function and as such are potentially useful factors for 
intervention in order to improve immune functioning.
In line with the evidence for psychosocial factors as potentially 
impacting on immune function, psychosocial interventions, 
particularly stress-management interventions and cognitive 
behavioral therapies, have been shown to affect indicators of 
immune function, such as lymphocyte counts, pro-inflammatory 
cytokine levels, or inflammatory activity (32–34). Evidence for 
the beneficial effects of interventions at this level is somewhat less 
consistent than for stress research, particularly due to the lower 
number of studies systematically measuring the same immune-
related outcome parameters. Corresponding findings across 
diseases for both psychosocial factors, such as stress, and psycho-
social interventions, such as stress-management interventions, 
suggest the involvement of common psychosocial mechanisms 
both in a fit and disturbed immune function, independent of the 
disease-specific pathogenic mechanisms.
At a molecular and cellular level several known neuro–immune 
interactions also support these findings. For instance, neurons 
produce cytokines and express “immunological receptors” like 
toll-like, immunoglobulin, cytokine, and chemokine receptors. 
Vice versa, immune cells produce neuropeptides and neurotrans-
mitters and express their receptors (35, 36). The bidirectional 
loop between immune and nervous system was also highlighted 
by the fact that CID patients have an elevated risk for depression 
(37–40).
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In view of the common psychological mechanisms that 
seem to play a role for both a fit and disturbed immune func-
tion, independent of the disease-specific pathways, integrated 
research strategies across conditions are needed. However, 
knowledge about possible common processes is not yet 
systematically used and integrated in the disease-oriented 
research traditions. Consequently, different lines of research 
usually independently exist, and exchange of knowledge across 
diseases or for both diseases and well-functioning immune 
function is very limited. Integration of knowledge from dif-
ferent disciplines enables an integrated theoretical and clinical 
approach that takes into account both the role of disease-
specific and generic psychosocial and biological factors as well 
as their possible interactions in stimulating and disturbing 
immune function for both healthy subjects and patients, with 
the ultimate goal to better understand immune function across 
health and disease.
Lifestyle Factors
We are what we eat and where or how we live (41). The envi-
ronment shapes our immune system. It is now well-known that 
lifestyle (e.g., diet, drinking) has an enormous influence on our 
immune system directly or indirectly through the microbiome 
(42–46). Also, the duration of exposure to lifestyle factors (our 
age) is an important factor, as are many other mostly under-
investigated factors such as sleep rhythm. To demonstrate just 
the tip of the iceberg in lifestyle factors potentially impacting 
on immune function, two factors are discussed here, intestinal 
microbiome and physical activity.
The intestinal microbiota contributes to human health 
through its ability to release energy and nutrients from food as 
well as regulating host immune and metabolic functions (47). 
The microbiota lives in symbiosis with the host. In the adult 
human, the two main phyla are Firmicutes, Gram-positive 
bacteria, and Bacteroidetes, Gram-negative bacteria (48). The 
development of the intestinal microbiota blueprint occurs in 
the first 1,000 days of life and is a dynamic process influenced 
by mode of delivery, antibiotic use, and early-life nutrition (49). 
Many experimental models show that the gut microbiota is vital 
for normal immune development and regulation (50). Pioneer 
bacteria colonizing the infant intestinal tract and gradual 
diversification toward a stable gut ecosystem play a crucial role 
in establishing stable host–microbe interactions and an optimal 
symbiosis between them. A crucial step in healthy postnatal 
microbiota development is the developing mucosal immune 
system that distinguishes between beneficial and pathogenic 
(microbial) entities. As such, an altered microbiota composi-
tion in early or later life can be linked to a number of CIDs 
(51). In addition, there is a parallel and interacting microbiota 
and immune system development throughout the life span with 
critical periods such as early life, but also adolescence (52–54) 
and old age (55–58), the latter possibly more involved in late-
onset CIDs. Although multifactorial aspects are involved in 
CIDs, changes in microbiota and activity are implicated in a 
broad range of these chronic conditions (43). The altered intes-
tinal colonization patterns in CIDs are associated with reduced 
microbial diversity as a common denominator. All of this is 
regarded as dysbiosis: “an imbalanced microbiota composition 
and/or activity, which disrupts the host–microbiota homeo-
stasis” (59, 60), resulting in an overactive immune response 
associated with CIDs.
An additional environmental factor with possible pro-
nounced effects on the function of the immune system is physical 
activity (61). It is, for instance, often reported that walking a 
marathon is not healthy, which has been confirmed in studies 
in recreational marathon runners showing a number of adverse 
changes in diverse immune system components that may leave 
the individual more susceptible to infectious diseases for a short 
time period (62). In line with this, several immune parameters 
have been shown to be suppressed when people train intensively 
for a prolonged period of time, including decrease of neutrophil 
function, immunoglobulin concentration, and natural killer cell 
counts, being associated with increased infection susceptibility 
(61, 63–65). On the other hand, epidemiological data show that 
regular moderate physical activity contributes to the prevention 
of disease and promotion of health (63, 64). Recently, in a system-
atic review based on studies examining PBMC gene expression, 
it has been demonstrated that prolonged and regular physical 
activity promotes inflammation dampening effects, possibly 
resulting in a reduced risk for the development or exacerbation 
of CIDs (66).
cHALLeNGes: eMBrAciNG 
cOMPLeXitY
integrating and extending Data and 
including immune system Dynamics
Considering the immune system, there is still a giant leap between 
the current limited sets of parameters determined in the various 
consortia (67–70) and the actual usage of the data for integration, 
as depicted in Table 1, there are many parameters of the immune 
system that can be measured, but most initiatives limit measure-
ments to a subset of parameters based on genetics or immune 
phenotyping.
The main paradox in most current approaches is that measur-
ing static immune function parameters does not comply with 
the fact that the immune system is a reactive as well as a dynamic 
system. Checking a static situation by a single measurement of 
serum proteins at a certain point in time does not reflect the 
response capacities of an individual’s immune system. An 
already well-explored option is to perform longitudinal ex 
vivo experiments with (isolated) blood or tissue-derived cells 
of the person in question and expose these cells to a number 
of different relevant immune stimuli, such as bacterial and 
viral compounds or immune proteins (cytokines or immuno-
globulins) (71). An obvious, albeit inevitable, limitation of this 
approach is that the cells are removed from their physiological 
context and placed in an artificial culture system. Nevertheless, 
these experiments can show us the dimensions and variability 
of the response to distinct immunological stimuli. From these 
data, network representations of the immune system that reflect 
the dynamic feedback-regulated interactions involving many 
different components can be constructed (72). In addition, we 
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will need to include as much information as possible about (epi)
genetic, transcriptomic, proteomic, environmental, and psycho-
sociological factors. When including the last mentioned factors 
into the equation, human research is inevitable and calls for new 
techniques from the field of big data science to be able to iden-
tify essential interactions between the immune system and its 
internal and external surrounding systems. Furthermore, new 
techniques are needed to describe and simulate the behavior of 
the immune system as a complex adaptive system. For this we 
suggest to apply complex adaptive systems science, for example, 
those that are successfully applied in studying and modeling of 
ecosystems (73).
Measures for Healthy systems Behavior
In its interaction with other physiological systems in the body 
and its versatile reaction to external factors, the immune system 
of a person might show typical behaviors that could indicate 
susceptibility to certain CIDs. The systematic investigation of this 
system behavior requires measurement methods that include the 
system’s dynamics.
In 2008, Mark Davis, immunologist at Stanford University, 
asked the question “How is my immune system?” and elaborated 
on the fact that we are unable to give an answer, because we 
lack metrics of immunological health in humans (74). To 
develop such metrics, we need to start developing meaningful 
metrics for the behavior, adaptiveness, and responsiveness of 
the system as a whole. These metrics could be a measure for 
the “fitness” of the immune system. Currently, our knowledge 
does not allow us to determine the immune fitness of an 
individual and, consequently, it is impossible to determine 
how (much) an individual patient’s immune function deviates 
from a fit immune system. Such a view would also help us to 
define and understand different degrees of immune fitness. 
The big immunological picture will enable us to treat patients 
much more efficiently and effectively and successfully revert 
the “sick” immune system to a fit state. It will also help healthy 
individuals to stay fit. The depicted immune reaction process 
in Figure 1B is a simplified attempt to describe the behavior, 
adaptiveness, and responsiveness of the system as a whole, in 
order to demonstrate that a different approach can lead to help-
ful new ideas. In Figure 1C, a selection of qualitative criteria 
are shown that are derived from this approach and that could 
be developed into quantitative and normative criteria for the 
behavior of the immune system.
tABLe 1 | scope of consortia.
Parameters Omics immune Psychosocial
G
enom
e/exom
e 
sequencing/S
M
P
s
E
pigenetics/
transcriptom
e Variation
P
roteom
ics/
m
etabolom
ics
M
icrobiom
ics
Vaccination response
Im
m
une (cell) 
phenotyping
C
ytokine/ chem
okine 
variation
S
ocioeconom
ic data
Q
uality of life
S
tress perception and 
coping
P
ersonality 
characterization
Life style (f.i. diet, sleep 
exercise)
Human Microbiome Project  
http://hmpdacc.org
The Immunological Genome Project 
(mouse)  
https://www.immgen.org
Immvar http://www.immvar.org/
ImmVar.swf
Personal Genome Project  
http://www.personalgenomes.org
Genotype Tissue Expression 
Consortium  
http://www.gtexportal.org
Stanford Medicine Centers  
http://med.stanford.edu
100k Wellness Project  
https://www.systemsbiology.org
Milieu Intérieur Consortium  
http://www.milieuinterieur.fr
Human Functional Genomics  
Project  
http://humanfunctionalgenomics.org
Data derived from the indicated websites.
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the Need to integrate experience-Based 
Knowledge
We are in great need for innovative multidisciplinary scientific 
research that enriches immunological knowledge with experi-
ence-based knowledge of a large group of CID patients, which 
incorporates a broad view on health, including psychosocial and 
lifestyle aspects (75).
A way to integrate experience-based knowledge into scientific 
research directly from the source (the patients themselves) is to 
translate patient narratives into hypotheses and include data 
from the narratives into the all-encompassing analyses. By 
designing a specific mix of qualitative, story-provoking ques-
tions and quantitative questions that have been designed to 
add meaning to certain aspects of their narratives, patients are 
invited to tell about their experiences with their CID(s) from 
their own perspective (76). For instance, patients could tell about 
life events that might be associated with their CID(s) or lifestyle 
factors that, to their experience, influence their disease activity. 
When a sufficient number of narratives will be collected, an 
evaluation and analysis of the narratives can point out certain 
patterns that emerge. If both the design of the questions and the 
evaluation of the narratives are done by a group that includes not 
only scientists and specialists but also patients, this bottom-up 
“participatory narrative inquiry” method is a powerful method 
for gaining unexpected insights and leads in the complex domain 
of CIDs.2
For the analysis of (extended) immune system (sub)phe-
notypes, we need to collect multiple data from well-defined 
patients and healthy volunteer cohorts, using a multidisci-
plinary and longitudinal approach. Collaboration between 
immunologists, computational biologists, patients, and their 
family suffering from CID(s), computer scientists, health-care 
professionals, physicians, psychologists, sociologists, physi-
ologists, physicists, pharmacologists, pharmacists, micro-
biologists, dieticians, and others is essential to find creative 
ideas and solutions to complex problems [see also Ref. (77) on 
collaborations]. Current genotype–phenotype databases have 
their limitations because they are generally disease-focused, 
not publicly available, and contain incomplete data and anno-
tation (78). We should collect as many individual data as we 
can, without overlooking things because of prior exclusion 
of supposedly irrelevant information or only include those 
hypothesized to be directly involved, to be able to find new 
subtypes as well as common pathways of CIDs, and additionally 
possible prevention strategies and new ways of treatment (79). 
In this way, we will refrain from the reductionist view that is 
based on incomplete knowledge of the biological mechanisms 
of gene functions in isolated cells and tissues or in inbred mice. 
From the analysis of these data, new hypotheses can be gener-
ated (80). To ensure transparency, reproducibility, and reus-
ability, the data management should be guided by the recently 
published FAIR (Findability, Accessibility, Interoperability, 
and Reusability) data principles (81).
2 http://www.workingwithstories.org/WorkingWithStoriesThirdEdition_Web.pdf.
Both top-down and bottom-up approaches (82–84) can be 
used to investigate the commonalities between different CIDs. 
Using top-down approaches and data from public resources, 
one may attempt to reconstruct biological networks that are 
common in multiple CIDs. Alternatively, bottom-up approaches 
can be used to develop and integrate smaller but more detailed 
mathematical models to understand properties of the immune 
system. The integration of psychosocial factors is only possible 
when data are available from studies in which these factors were 
actually assessed, which generally will not be the case. Therefore, 
we believe that additional large-scale studies are required to 
investigate the effects of such factors on biological networks. 
Bottom-up approaches may also be used to study perturbation 
of disease pathways involved in comorbidity. This requires 
knowledge of such pathways. (Hypothesized) Psychosocial effects 
might be included in such mathematical models. To the best of 
our knowledge, top-down and bottom-up approaches have not 
yet been used to study commonalities in CIDs. Using these 
approaches, the comparison of patients with CIDs and healthy 
individuals may lead to a better definition of immune fitness. 
With this approach, we might also be able to learn to understand 
the physiology of unexplained complaints such as discomfort and 
fatigue.
Once we were able to determine the boundaries and dynamics 
of an adequate immune reaction, it is possible to identify aber-
rances in patients with CIDs. In this way, we might find an answer 
to the question whether derailing immunity is a consequence of 
a high (or low) responsive state in groups of patients determined 
by a certain genetic and environmental make-up. By doing so, we 
can develop comprehensive risk models that integrate a certain 
immune status with extensive omics and a broad environmental 
risk profiles that includes cognitive, emotional, dietary, and 
social risk factors. This will result in tools such as biomarkers and 
predictive algorithms that can support prevention and clinical 
management.
cONcLUsiON
In this position document, we propose the concept that elucidat-
ing treatment and prevention of CIDs can be much accelerated 
when we start connecting diseases to underlying processes and 
place disease mechanisms at a molecular and cellular level in a 
much broader perspective. In order to understand which (com-
mon) factors contribute to the onset or exacerbation of CIDs and 
which mechanisms keep the immune system in homeostasis or 
drive the system into disease states, components such as life style, 
emotions, cognitions, and behaviors must also be incorporated. 
Current computational and complexity science will allow us to 
generate insight into the complex behavior of the whole system 
if we dare to start developing new techniques from this field and 
apply it to unravel the big picture.
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